Boehringer Ingelheim Corporation and EFSD Announce First Recipients of Diabetes Research Funding

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The Boehringer Ingelheim (BI) and European Foundation for the Study of Diabetes (EFSD) partnership today announced the recipients of their European-wide funding initiative targeted at diabetes research. Totalling €2.5 million, these are the first grants to be awarded as part of the EFSD/Boehringer Ingelheim European Diabetes Research Programmes, which aim to stimulate and accelerate European research in diabetes.

Help employers find you! Check out all the jobs and post your resume.

Back to news